Nikoletta Lendvai

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Characterization of a Murine Monoclonal Antibody to<i>Cryptococcus neoformans</i>Polysaccharide That Is a Candidate for Human Therapeutic Studies

Arturo Casadevall, Wendy Cleare, Marta Feldmesser et al. · Antimicrobial Agents and Chemotherapy · 1998 · 306 citations · Full text

Life Sciences, Immunology, Microbiology +16

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso et al. · Blood Cancer Journal · 2022 · 270 citations · Full text

Medicine, Hematology, Oncology +17

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat et al. · The Lancet Oncology · 2018 · 244 citations

Medicine, Oncology, Pharmacotherapy +16